Literature DB >> 29358741

The structure of serum resistance-associated protein and its implications for human African trypanosomiasis.

Sebastian Zoll1, Harriet Lane-Serff1, Shahid Mehmood2, Jonathan Schneider1, Carol V Robinson2, Mark Carrington3, Matthew K Higgins4.   

Abstract

Only two trypanosome subspecies are able to cause human African trypanosomiasis. To establish an infection in human blood, they must overcome the innate immune system by resisting the toxic effects of trypanolytic factor 1 and trypanolytic factor 2 (refs. 1,2). These lipoprotein complexes contain an active, pore-forming component, apolipoprotein L1 (ApoL1), that causes trypanosome cell death 3 . One of the two human-infective subspecies, Trypanosoma brucei rhodesiense, differs from non-infective trypanosomes solely by the presence of the serum resistance-associated protein, which binds directly to ApoL1 and blocks its pore-forming capacity3-5. Since this interaction is the single critical event that renders T. b. rhodesiense human- infective, detailed structural information that allows identification of binding determinants is crucial to understand immune escape by the parasite. Here, we present the structure of serum resistance-associated protein and reveal the adaptations that occurred as it diverged from other trypanosome surface molecules to neutralize ApoL1. We also present our mapping of residues important for ApoL1 binding, giving molecular insight into this interaction at the heart of human sleeping sickness.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29358741     DOI: 10.1038/s41564-017-0085-3

Source DB:  PubMed          Journal:  Nat Microbiol        ISSN: 2058-5276            Impact factor:   17.745


  8 in total

Review 1.  APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.

Authors:  Pazit Beckerman; Katalin Susztak
Journal:  Trends Mol Med       Date:  2018-06-07       Impact factor: 11.951

2.  Visualisation of experimentally determined and predicted protein N-glycosylation and predicted glycosylphosphatidylinositol anchor addition in Trypanosoma brucei.

Authors:  Michele Tinti; Michael A J Ferguson
Journal:  Wellcome Open Res       Date:  2022-01-31

3.  Structure of trypanosome coat protein VSGsur and function in suramin resistance.

Authors:  Johan Zeelen; Monique van Straaten; Joseph Verdi; Alexander Hempelmann; Hamidreza Hashemi; Kathryn Perez; Philip D Jeffrey; Silvan Hälg; Natalie Wiedemar; Pascal Mäser; F Nina Papavasiliou; C Erec Stebbins
Journal:  Nat Microbiol       Date:  2021-01-18       Impact factor: 17.745

4.  Nucleotide sugar biosynthesis occurs in the glycosomes of procyclic and bloodstream form Trypanosoma brucei.

Authors:  Maria Lucia Sampaio Guther; Alan R Prescott; Sabine Kuettel; Michele Tinti; Michael A J Ferguson
Journal:  PLoS Negl Trop Dis       Date:  2021-02-16

5.  A multifaceted strategy to improve recombinant expression and structural characterisation of a Trypanosoma invariant surface protein.

Authors:  Hagen Sülzen; Jitka Votrubova; Arun Dhillon; Sebastian Zoll
Journal:  Sci Rep       Date:  2022-07-26       Impact factor: 4.996

6.  Structures of the ApoL1 and ApoL2 N-terminal domains reveal a non-classical four-helix bundle motif.

Authors:  Mark Ultsch; Michael J Holliday; Stefan Gerhardy; Paul Moran; Suzie J Scales; Nidhi Gupta; Francesca Oltrabella; Cecilia Chiu; Wayne Fairbrother; Charles Eigenbrot; Daniel Kirchhofer
Journal:  Commun Biol       Date:  2021-07-27

7.  A small molecule inhibitor of HER3: a proof-of-concept study.

Authors:  Audrey Colomba; Martina Fitzek; Roger George; Gregory Weitsman; Selene Roberts; Laura Zanetti-Domingues; Michael Hirsch; Daniel J Rolfe; Shahid Mehmood; Andrew Madin; Jeroen Claus; Svend Kjaer; Ambrosius P Snijders; Tony Ng; Marisa Martin-Fernandez; David M Smith; Peter J Parker
Journal:  Biochem J       Date:  2020-09-18       Impact factor: 3.766

Review 8.  Genetic and immunological basis of human African trypanosomiasis.

Authors:  Etienne Pays; Derek P Nolan
Journal:  Curr Opin Immunol       Date:  2021-03-12       Impact factor: 7.486

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.